Acute Kidney Injury Treatment Market by Product (Dialysis, Drug Therapy), Injury (Pre-renal Injury, Intrinsic Renal Injury, Post-renal Injury), Distribution Channel (Hospitals, Ambulatory Surgical Centers) & Region for 2024-2031

Acute Kidney Injury Treatment Market Valuation - 2024-2031

The Acute Kidney Injury (AKI) therapy market is expanding due to rising prevalence of kidney-related illnesses and increasing awareness. Dialysis, medicine and supportive care are among the most important treatments. Technological developments and enhanced diagnostic methods both contribute to market growth. This is likely to enable the market size surpass USD 1.51 Billion valued in 2024 to reach a valuation of around USD 2.56 Billion by 2031.

Rising chronic disorders such as diabetes and hypertension are propelling the AKI therapy market. However, high treatment costs and low awareness in developing countries provide obstacles. Government initiatives and improvements to healthcare infrastructure are critical for market growth, as is continued research into breakthrough therapeutics. The rising demand for acute kidney injury treatment is enabling the market grow at a CAGR of 6.85% from 2024 to 2031.

Acute Kidney Injury Treatment Market: Definition/ Overview

Acute Kidney Injury (AKI) treatment consists of addressing the underlying cause, maintaining fluid balance and supporting kidney function. This involves drugs, dialysis if necessary and monitoring electrolyte and waste levels to avoid problems and enhance recovery.

Acute kidney injury (AKI) treatment focuses on addressing the underlying cause, restoring kidney function and avoiding complications. Common interventions include hydration control, electrolyte balance, medicine and dialysis. Early diagnosis and treatment are critical for avoiding permanent kidney damage and improving patient outcomes.

Advances in early detection, customized therapeutics and regenerative medicine will shape the treatment of Acute Kidney Injury (AKI). Innovations such as biomarker-based diagnostics and stem cell therapies are projected to enhance patient outcomes by slowing the progression of chronic kidney disease and improving overall kidney function.

Will Rising Prevalence of Chronic Diseases Boost the Growth of Acute Kidney Injury Treatment Market?

The rising incidence of chronic disorders including diabetes and hypertension is a major driver driving the acute kidney injury (AKI) therapy market. According to the Centers for Disease Control and Prevention (CDC), around 37 million US individuals have chronic kidney disease (CKD), which is frequently undetected in the early stages.

According to the NIDDK, AKI affects 5-7% of hospitalized patients and up to 20% of critically ill patients acquire AKI. The USRDS 2020 Annual Data Report cites a rise in CKD prevalence among Medicare beneficiaries, while the National Kidney Foundation emphasizes the significant impact of diabetes and hypertension on CKD patients. Furthermore, the prevalence of AKI has increasing dramatically, highlighting the urgent need for better treatments.

Will High Cost of Treatment Hamper the Acute Kidney Injury Treatment Market?

The high cost of treatment for acute kidney injury (AKI) may limit market expansion. A study published in the National Library of Medicine found that the average hospitalization cost for AKI patients is $24,896, compared to $13,425 for individuals without AKI. This $11,471 additional cost associated with AKI may be a considerable financial burden for people and healthcare systems.

Furthermore, the high costs associated with modern diagnostic and therapeutic approaches may impede access to timely and effective care. This economic constraint may hinder market growth, especially in areas with inadequate healthcare resources or insufficient insurance coverage.

Category-Wise Acumens

Will Decreasing Blood Flow to the Kidneys Drive the Injury Segment?

A decrease in blood supply to the kidneys will cause the acute kidney injury (AKI) phase. Reduced renal perfusion is the major cause of AKI, which is frequently caused by severe dehydration, shock, or heart failure. When blood flow is reduced, the kidneys cannot filter waste adequately, resulting in kidney injury. This pathophysiological mechanism contributes significantly to AKI cases, emphasizing the need of targeting decreased renal perfusion in therapeutic efforts.

The growing awareness and emphasis on controlling and avoiding diseases that cause reduced blood flow to the kidneys is expected to fuel growth in the AKI therapy segment. Early detection and intervention are critical for reducing harm and improving patient outcomes, which encourages the development of focused medicines and diagnostic technologies in this area.

Will Increasing Demand for Managing Kidney Failure by Removing Waste Drive the Dialysis Segment?

The dialysis segment will be driven by an increase in demand for waste removal to manage renal failure. As kidney function deteriorates, dialysis becomes necessary to accomplish the crucial job of removing waste and excess fluid from the blood.

The rise in chronic renal disease, diabetes and hypertension, all of which contribute to kidney failure, emphasizes the importance of effective dialysis solutions. Advances in dialysis technology, as well as increasing awareness of its benefits, help to fuel this trend. With an increasing patient population requiring dialysis, driven by the increasing prevalence of kidney failure, demand for dialysis treatments is likely to rise further, propelling innovation and market expansion in this sector.

Country/Region-wise Acumens

Will High Prevalence of Chronic Diseases Drive the Market in North America?

The rising prevalence of chronic diseases will propel the AKI therapy market in North America. Chronic illnesses common in the region, such as diabetes and hypertension, are important risk factors for acute kidney injury. With millions of people impacted by these disorders, there is an increasing demand for better AKI treatments.

North America's modern healthcare system and high level of care encourage the use of novel medicines and technologies to manage and treat AKI. Furthermore, large investments in R&D, together with increasing awareness of kidney health, contribute to market growth. As chronic disease rates rise, the demand for AKI therapies will stay high, fueling market growth in North America.

Will Increasing Awareness of Kidney Diseases Drive the Market in Asia Pacific Region?

The acute kidney injury (AKI) treatment market in Asia-Pacific will grow due to increasing awareness of kidney illnesses. Growing public and healthcare professional awareness of the prevalence, risk factors and implications of kidney disease is resulting in earlier diagnosis and more proactive treatment. This increasing awareness fuels demand for new diagnostic tools and treatment choices.

Furthermore, educational initiatives and government health programs aiming at improving kidney health help to drive market growth. As the public gets more educated about kidney disease prevention and management, there will be a greater uptake of AKI treatments, driving market growth. Improved awareness contributes to the overall development of healthcare infrastructure and encourages investment in medical technologies, increasing regional market growth.

Competitive Landscape

The acute kidney injury treatment market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the acute kidney injury treatment market include:

Baxter International, Inc.

Fresenius Medical Care AG & Co KGaA

Braun Melsungen AG

Angion Biomedica Corp

AM-Pharma

Quark Pharmaceuticals, Inc.

Asahi Kasei Medical Co Ltd

LG Chem

Acute Kidney Injury Treatment Market Latest Developments

In March 2021, B. Braun Avitum AG, a major manufacturer of medical equipment and pharmaceutical products and services and CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat fatal inflammation, announced the partnership launched a global co-marketing agreement to promote the usage of CytoSorb.

In March 2021, Critical Path Institute (C-Path), a nonprofit organization, announced the commencement of the Acute Kidney Injury (AKI) Project in partnership with the US Food and Drug Administration. The business proposes creating prognostic tools to better anticipate and identify drug-induced kidney damage (DIKI).

In November 2020, Vifor Pharma, a Swiss medicine maker, agreed to pay Angion Biomedica up to USD 80.0 Million for rights to experimental kidney drug ANG-3777

Acute Kidney Injury Treatment Market, By Category

• Product:
• Dialysis
• Intermittent Hemodialysis
• Continuous Renal Replacement Therapy (CRRT)
• Sustained Low-Efficiency Dialysis (SLED)
• Drug Therapy
• Antibiotics
• Diuretics
• Immunosuppressive Agents
• Injury:
• Pre-renal Injury
• Intrinsic Renal Injury
• Post-renal Injury
• Distribution Channel:
• Hospitals
• Ambulatory Surgical Centers
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa